Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
Author Information
Author(s): Glockzin Gabriel, Schlitt Hans J, Piso Pompiliu
Primary Institution: Department of Surgery, University of Regensburg Medical Center, Regensburg, Germany
Hypothesis
Can cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improve survival and quality of life in patients with peritoneal carcinomatosis?
Conclusion
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can improve patient survival and quality of life for selected patients with peritoneal carcinomatosis.
Supporting Evidence
- CRS and HIPEC can improve survival rates in patients with peritoneal carcinomatosis.
- The completeness of cytoreduction is a key predictor of patient outcomes.
- Quality of life can improve after surgery despite initial complications.
Takeaway
Doctors can help some patients with advanced cancer in their belly feel better and live longer by using a special surgery and heated medicine.
Methodology
This review article discusses preoperative workup, surgical techniques, postoperative morbidity and mortality rates, oncological outcomes, and quality of life after CRS and HIPEC.
Limitations
The assessment of morbidity is not standardized across studies, making comparisons difficult.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website